A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Trial Profile

A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adrenocortical carcinoma; Genitourinary disorders; Penile cancer; Prostate cancer; Tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 08 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Jan 2018.
    • 09 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top